SEC Company Response from Theriva Biologics, Inc. (TOVX) (CIK 0000894158) (TOVX) — May 14, 2018

Theriva Biologics, Inc. (TOVX) (CIK 0000894158)
Date: May 14, 2018 · CIK: 0000894158 · Accession: 0001144204-18-028259

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

File numbers found in text: 333-224728, 333-22478

Date

May 14, 2018

Author

Steven A. Shallcross

Form

CORRESP

Company

Theriva Biologics, Inc. (TOVX) (CIK 0000894158)

Letter

Synthetic Biologics, Inc.

9605 Medical Center Drive, Suite 270

Rockville, Maryland 20850

May 14, 2018

VIA EDGAR

United States Securities

and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, D.C. 20549

Attention: Ms. Dorrie Yale

Re: Synthetic Biologics, Inc.

Registration Statement on Form S-3

File No: 333-224728

Ladies and Gentlemen:

Synthetic Biologics, Inc. (the “Registrant”) hereby requests that the United States Securities and Exchange Commission (the “Commission”) take appropriate action to cause the above-referenced Registration Statement on Form S-3 (File No. 333-22478), to become effective on Tuesday, May 15, 2018, at 4:00 p.m., Eastern Time, or as soon thereafter as is practicable.

The Registrant hereby authorizes its counsel, Leslie Marlow, Esq. of Gracin & Marlow, LLP, to orally modify or withdraw this request for acceleration. Please contact Ms. Marlow at (516) 496-2223 or (212) 907-6457 with any questions you may have concerning this request, and please notify her when this request for acceleration has been granted.

Very truly yours,
Synthetic Biologics, Inc.

Show Raw Text

CORRESP
1
filename1.htm

    

Synthetic Biologics, Inc.

9605 Medical Center Drive, Suite 270

Rockville, Maryland 20850

    May 14, 2018

VIA EDGAR

United States Securities

    and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, D.C. 20549

Attention: Ms. Dorrie Yale

    Re:
    Synthetic Biologics, Inc.

Registration Statement on Form S-3

File No: 333-224728

Ladies and Gentlemen:

Synthetic Biologics,
Inc. (the “Registrant”) hereby requests that the United States Securities and Exchange Commission (the “Commission”)
take appropriate action to cause the above-referenced Registration Statement on Form S-3 (File No. 333-22478), to become effective
on Tuesday, May 15, 2018, at 4:00 p.m., Eastern Time, or as soon thereafter as is practicable.

The Registrant hereby authorizes its counsel, Leslie Marlow, Esq. of Gracin & Marlow, LLP, to orally modify or withdraw this
request for acceleration. Please contact Ms. Marlow at (516) 496-2223 or (212) 907-6457 with any questions you may have concerning
this request, and please notify her when this request for acceleration has been granted.

    Very truly yours,

    Synthetic Biologics, Inc.

    By: /s/ Steven A. Shallcross

    Name:
    Steven A. Shallcross

    Title:

        Interim Chief Executive Officer and

        Chief Financial Officer

 cc: Leslie
Marlow, Esq., Gracin & Marlow, LLP

SecProbe.io